Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction (GCQOL01)
The purpose of this study is to find out more about differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction. To find a better reconstruction for patients who received total gastrectomy.
Adenocarcinoma of Esophagogastric Junction.
Other: Total Gastrectomy or Proximal Gastrectomy
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction|
- Change in QOL (Quality of Life) [ Time Frame: 5years ] [ Designated as safety issue: No ]From preoperative following gastrectomy, as measured with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-STO22 questionnaires.
- Nutritional status of patients [ Time Frame: 5 years ]
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||May 2017|
|Estimated Primary Completion Date:||May 2015 (Final data collection date for primary outcome measure)|
|Total Gastrectomy or Proximal Gastrectomy||Other: Total Gastrectomy or Proximal Gastrectomy|
Overall, the incidence of stomach cancer worldwide is declining with geographical variation. However, an increase in the incidence rate of adenocarcinoma of esophagogastric junction, called cardia or AEG has been observed in recent years. AEG may represent a specific histopathological and biologic entity. In the treatment AEG there is argument over whether proximal gastractomy(PG) or total gastractomy (TG) should be done. The quality of life (QOL) of the patients following TG or PG arouses people's attention. The purpose of this study was to evaluate differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01697917
|Contact: Wang Ya Nong, MD, PhD||+86-21 64175590 ext firstname.lastname@example.org|
|Contact: Huang Hua, MD,PhD||+86-21 64175590 ext email@example.com|
|Fudan University Shanghai Cancer Center||Recruiting|
|Shanghai, Shanghai, China, 200032|
|Contact: Ya Nong Wang, MD,PhD +86-21 64175590 ext 1208 firstname.lastname@example.org|
|Contact: Hua Huang, MD,PhD +86-21 64175590 ext 1205 email@example.com|